Mendor Announces CE Marking for its Diabetes Management Platform


ESPOO, Finland, June 18, 2013 /PRNewswire/ — Finnish technology company today the CE mark for its groundbreaking , Mendor Balance®. This cloud-based seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.

Mendor Balance enables people living with diabetes to effortlessly share their blood glucose monitoring results with their caregiver from most glucose meters in the market today. Balance provides professionals with a set of tools to efficiently manage a clinic full of patients, with a future pipeline of real-life decision support protocols.

CE Mark Considered an Important Milestone for Treatment Individualization

The IVD (in vitro diagnostic) products have a clearly defined regulatory environment which is currently not common practice in software development designed to support diabetes management. Mendor’s passionate team has been working extremely hard and built a product that meets all the regulatory specifications, now realized in the form of CE of Mendor Balance.

“I am very proud of our skillful software and clinical team for enabling the CE mark for Mendor Balance platform. This is the first CE marked meter agnostic platform in EU for storing and sharing blood glucose data. CE mark for Mendor Balance is an important step towards scalable and automated blood glucose analysis and decision support system, which are necessary features for blood glucose profiling and treatment individualization”, states Antti Virkamäki, Endocrinologist and the Medical Director of Mendor.

Built to Scale Up and Adapt to Real-Life Diabetes M anagement

Diabetes is a major global health challenge. Mendor Balance is designed to give a new tool set for tackling escalating costs and ever scarcer resources. Mendor is currently running a number of patient trials, where the tools for…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS